Top Rx IP Update Reads of 2019

We reviewed 2019’s top developments in Canadian life sciences IP and regulatory law in our highlights article.  Below were our top 10 reads:

#1 Update on biosimilars in Canada – October 2019

#2 Federal Court of Appeal requires PMPRB to re-determine whether patent ‘pertains to’ Galderma’s DIFFERIN

#3 Amgen not precluded by invalidity decision under pre-amended PMNOC Regulations from litigating same patent under amended regulations 

#4 Canada releases final amendments to Patented Medicines Pricing Regulations; in force July 1, 2020

#5 Project Orbis enables concurrent regulatory approval of LENVIMA and KEYTRUDA combination therapy in Canada, U.S. and Australia

#6 Amended PMNOC Regulations: Second Anniversary Update

#7 Federal Court issues two interlocutory decisions in section 8 pregabalin case

#8 Orders of prohibition relating to polymorphic form patent for PRISTIQ upheld on appeal

#9 Federal Court of Appeal confirms obviousness finding in section 8 bortezomib action against Teva

#10 Eli Lilly granted leave to add new cause of action of direct infringement of “composition for use” claims, absent allegation of direct infringement by patients